Short answer
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an 8-K current report with the SEC on June 10, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders), Item 8.01 (Other Events). 74% turnout with 329,492,680 shares represented, supporting strong investor participation.
IOVANCE BIOTHERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 74% turnout with 329,492,680 shares represented, supporting strong investor participation
- All six director nominees elected, with affirmative votes ranging from 181,341,958 to 186,590,407
- Executive compensation approved; future say-on-pay votes set for every 1 year
- Authorized common shares increased from 500,000,000 to 650,000,000, expanding potential equity issuance and dilution capacity
- Employee stock purchase plan expanded by 1,000,000 shares, increasing employee equity participation and potential dilution
Item 8.01 · Other Events
- Australian TGA marketing authorization for Amtagvi® in previously treated advanced melanoma
- Approval covers metastatic or unresectable melanoma patients
- Expands Amtagvi®’s commercial reach beyond existing markets
- Exhibit 99.1 contains the company’s approval announcement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IOVANCE BIOTHERAPEUTICS, INC. 8-K filings
Get the next IOVA 8-K as it lands
Follow IOVA for push alerts, or ask the research agent what this filing means.